Keywords: Stroke, Stroke, metabolismTwo common treatment paradigms for sickle cell disease (SCD) include oral medication hydroxyurea and blood transfusions. Rarely, a curative hematopoietic stem cell transplant (HSCT) is performed. We utilized non-invasive MRI to evaluate how potential biomarkers of infarct risk, cerebral blood flow (CBF) and oxygen extraction fraction (OEF), change in these treatment paradigms (cumulative n=39). Hydroxyurea treatment did not have significant changes to hemoglobin, CBF, or OEF between two scans. Hemoglobin increases by approximately 8.73 and 64.11% for adults with SCD on transfusion and transplant treatments, respectively. These changes most prominently parallel a reduction in CBF of 20.46 and 31.67%, respectively.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords